Trial · NCT00393718
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT00393718, Phase 3, Completed, Novo Nordisk A/S; results first posted 2010-03-12
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes. Trials, record NCT00393718. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00393718
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
- NCT number
- NCT00393718
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 400 participants, actual
- Lead sponsor
- Novo Nordisk A/S
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- liraglutide, glibenclamide, placebo, placebo
- First posted
- 2006-10-30
- Last updated
- 2017-03-08
- Results first posted
- 2010-03-12
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment | after 24 weeks of treatment | |
| Secondary | Glycosylated Haemoglobin A1c (HbA1c) After 52 Weeks of Treatment | after 52 weeks of treatment | |
| Secondary | Fasting Plasma Glucose After 24 Weeks of Treatment | after 24 weeks of treatment | |
| Secondary | Fasting Plasma Glucose After 52 Weeks of Treatment | after 52 weeks of treatment | |
| Secondary | Postprandial Glucose AUC After 24 Weeks of Treatment | after 24 weeks of treatment | Postprandial glucose AUC measured 0-3 hours after a meal after 24 weeks of treatment |
| Secondary | Postprandial Glucose AUC After 52 Weeks of Treatment | after 52 weeks of treatment | Postprandial glucose AUC measured 0-3 hours after a meal after 52 weeks of treatment |
| Secondary | Mean PG in 7-point Plasma Glucose Profile After 24 Weeks of Treatment | after 24 weeks of treatment | Plasma glucose (PG) profile measured after 24 weeks of treatment. The time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime. |
| Secondary | Mean PG in 7-point Plasma Glucose Profile After 52 Weeks of Treatment | after 52 weeks of treatment | Mean plasma glucose(PG) in 7-point plasma glucose profile measured after 52 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime. |
| Secondary | Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 24 Weeks of Treatment | after 24 weeks of treatment | Mean postprandial plasma glucose (PG) increment in 7-point plasma glucose profile, ie the mean of the difference of plasma glucose measured before and after a meal, after 24 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime. |
| Secondary | Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 52 Weeks of Treatment | after 52 weeks of treatment | Mean postprandial plasma glucose (PG) increment in 7-point plasma glucose profile, ie the mean of the difference of plasma glucose measured before and after a meal, after 52 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment | after 24 weeks of treatment | Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline. | percentage of total haemoglobin | LEAST_SQUARES_MEAN |
| SECONDARY | Glycosylated Haemoglobin A1c (HbA1c) After 52 Weeks of Treatment | after 52 weeks of treatment | Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline. | percentage of total haemoglobin | LEAST_SQUARES_MEAN |
| SECONDARY | Fasting Plasma Glucose After 24 Weeks of Treatment | after 24 weeks of treatment | Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline. | mg/dL | LEAST_SQUARES_MEAN |
| SECONDARY | Fasting Plasma Glucose After 52 Weeks of Treatment | after 52 weeks of treatment | Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline. | mg/dL | LEAST_SQUARES_MEAN |
| SECONDARY | Postprandial Glucose AUC After 24 Weeks of Treatment | after 24 weeks of treatment | Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline. | mg/dL *h | LEAST_SQUARES_MEAN |
| SECONDARY | Postprandial Glucose AUC After 52 Weeks of Treatment | after 52 weeks of treatment | Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline. | mg/dL *h | LEAST_SQUARES_MEAN |
| SECONDARY | Mean PG in 7-point Plasma Glucose Profile After 24 Weeks of Treatment | after 24 weeks of treatment | Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline. | mg/dL | LEAST_SQUARES_MEAN |
| SECONDARY | Mean PG in 7-point Plasma Glucose Profile After 52 Weeks of Treatment | after 52 weeks of treatment | Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline. | mg/dL | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 24 Weeks of Treatment | after 24 weeks of treatment | Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline. | mg/dL | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 52 Weeks of Treatment | after 52 weeks of treatment | Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline. | mg/dL | LEAST_SQUARES_MEAN |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 outcomesResults by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment | Liraglutide | 6.99 | Standard Error 0.07 | percentage of total haemoglobin | |
| Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment | Glibenclamide | 7.50 | Standard Error 0.09 | percentage of total haemoglobin | |
| Glycosylated Haemoglobin A1c (HbA1c) After 52 Weeks of Treatment | Liraglutide | 7.31 | Standard Error 0.08 | percentage of total haemoglobin | |
| Glycosylated Haemoglobin A1c (HbA1c) After 52 Weeks of Treatment | Glibenclamide | 7.80 | Standard Error 0.10 | percentage of total haemoglobin | |
| Fasting Plasma Glucose After 24 Weeks of Treatment | Liraglutide | 137.2 | Standard Error 1.9 | mg/dL | |
| Fasting Plasma Glucose After 24 Weeks of Treatment | Glibenclamide | 150.1 | Standard Error 2.5 | mg/dL | |
| Fasting Plasma Glucose After 52 Weeks of Treatment | Liraglutide | 145.8 | Standard Error 2.4 | mg/dL | |
| Fasting Plasma Glucose After 52 Weeks of Treatment | Glibenclamide | 157.5 | Standard Error 3.2 | mg/dL | |
| Postprandial Glucose AUC After 24 Weeks of Treatment | Liraglutide | 557.54 | Standard Error 9.53 | mg/dL *h | |
| Postprandial Glucose AUC After 24 Weeks of Treatment | Glibenclamide | 670.60 | Standard Error 12.69 | mg/dL *h |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Liraglutide | 268 | |
| Overall Study | STARTED | Glibenclamide | 132 | |
| Overall Study | COMPLETED | Liraglutide | 225 | |
| Overall Study | COMPLETED | Glibenclamide | 110 | |
| Overall Study | NOT COMPLETED | Liraglutide | 43 | |
| Overall Study | NOT COMPLETED | Glibenclamide | 22 |
Source ClinicalTrials.gov
Adverse events96
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Liraglutide | 100 | 268 | 183 |
| other | Nasopharyngitis | Infections and infestations | Glibenclamide | 57 | 132 | 94 |
| other | Bronchitis | Infections and infestations | Liraglutide | 11 | 268 | 13 |
| other | Bronchitis | Infections and infestations | Glibenclamide | 8 | 132 | 11 |
| other | Diarrhoea | Gastrointestinal disorders | Liraglutide | 26 | 268 | 31 |
| other | Diarrhoea | Gastrointestinal disorders | Glibenclamide | 9 | 132 | 12 |
| other | Constipation | Gastrointestinal disorders | Liraglutide | 21 | 268 | 23 |
| other | Constipation | Gastrointestinal disorders | Glibenclamide | 7 | 132 | 8 |
| other | Stomach discomfort | Gastrointestinal disorders | Liraglutide | 14 | 268 | 21 |
| other | Stomach discomfort | Gastrointestinal disorders | Glibenclamide | 3 | 132 | 5 |
1 to 10 of 96Source ClinicalTrials.gov
See all 96 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Liraglutide | ||
| Total, all-cause mortality | Glibenclamide | ||
| Total, other adverse events | Liraglutide | 172 | 268 |
| Total, other adverse events | Glibenclamide | 91 | 132 |
| Total, serious adverse events | Liraglutide | 20 | 268 |
| Total, serious adverse events | Glibenclamide | 14 | 132 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Liraglutide vs Glibenclamide: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00393718
GET https://conductscience.org/api/trials/v1/NCT00393718/results?page=2